Dow Jones
34.297,73 -66,77 (-0,19%) Nasdaq
13.539,29 -315,83 (-2,28%) Nikkei 225
27.131,34 -457,03 (-1,66%) EUR/USD
1,1303 -0,0027 (-0,24%) BTC-EUR
32.456,65 -314,68 (-0,96%) CMC Crypto 200
831,82 +11,23 (+1,37%)
AstraZeneca PLC (AZN.ST)
- GlobeNewswire
Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China
Collaboration highlights the value of MRD solid tumor data generated by Genetron’s Mutation Capsule platform, and further accelerates product developmentBEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collabor
- GlobeNewswire
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET — HONG KONG and FLORHAM PARK, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:AZN) have initiated SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (
